We are advancing three formulations of alicaforsen for the treatment of inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis. In addition, we are building a clinical pipeline in renzapride for the treatment of gut motility.

Alicaforsen is a novel antisense oligonucleotide targeted to down regulate the production of ICAM-1, a cell surface receptor which is involved in the process of inflammation.

Renzapride is considered best in class orally bioavailable small molecule with a dual mode of action which can increase gut motility and reduce nausea and vomiting.